Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older

Affiliations

¹ Klinik für Innere Medizin I, Friedrich-Schiller-Universität Jena, Universitätsklinikum Jena, Jena, Germany.
² Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
³ Institut für Klinische Chemie und Klinische Pharmakologie, Universitätsklinikum Bonn, Bonn, Germany.

Comment

Oliver Weingärtner et al. JAMA Cardiol. 2020.

. 2020 Feb 1;5(2):234.

doi: 10.1001/jamacardio.2019.5197.

¹ Klinik für Innere Medizin I, Friedrich-Schiller-Universität Jena, Universitätsklinikum Jena, Jena, Germany.
² Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
³ Institut für Klinische Chemie und Klinische Pharmakologie, Universitätsklinikum Bonn, Bonn, Germany.

No abstract available

Comment in

Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply.
Bach RG, Cannon CP, Blazing MA. Bach RG, et al. JAMA Cardiol. 2020 Feb 1;5(2):235-236. doi: 10.1001/jamacardio.2019.5241. JAMA Cardiol. 2020. PMID: 31895449 No abstract available.

Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial.
Bach RG, Cannon CP, Giugliano RP, White JA, Lokhnygina Y, Bohula EA, Califf RM, Braunwald E, Blazing MA. Bach RG, et al. JAMA Cardiol. 2019 Sep 1;4(9):846-854. doi: 10.1001/jamacardio.2019.2306. JAMA Cardiol. 2019. PMID: 31314050 Free PMC article. Clinical Trial.